Prestige Consumer Expects 4% Sales Dip For Its FY2021 As COVID-19 Clouds Economic Forecast
Executive Summary
North American sales for the consumer health segment in the quarter reached $216.6m core products on women’s health, analgesics, oral care and ear and eye care categories, partially offset by declines in cough and cold products as well as gastrointestinal products.
You may also be interested in...
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
Prestige Consumer’s ‘Nimble’ Marketing Helps Beat Fiscal 2021 Guidance
Less travel, closed schools and a slower cold/cough season during the pandemic required Prestige Consumer to invest strategically across its OTC healthcare portfolio in fiscal 2021. Dramamine motion sickness and Nix head lice treatments got less attention, while Monistat, Compound W and Clear Eyes received more.
Seeing Light At End Of Pandemic Tunnel, Prestige Consumer Healthcare Raises Earnings Guidance
Prestige Consumer Healthcare prepares to “lap the effects” of COVID-19 disruption on, estimating its fiscal year 2021 sales will reach $935m, ahead of earlier projections, and maintaining long-term organic growth targets of 2%-3%.